| abstract |
The present invention relates to an anti-ILDR2 antibody, a fragment or derivative thereof, a modified antibody format, or an antibody mimetic for use in combination with a PD-1 antagonist in the treatment of cancer. Other aspects of the present invention relate to a combination comprising an anti-ILDR2 antibody and a PD-1 antagonist and the use of such combination as a medicament, as well as methods of treatment or prophylaxis of a cancer in a subject, comprising administering to said subject a therapeutically effective amount of the antibodies as described herein. Further, the present invention relates to a kit comprising anti-ILDR2 antibodies and PD-1 antagonists and optionally one or more further pharmaceutical agents. |